Floatz logo

Adx-324

Hereditary Angioedema - Type 2

ADARx Pharmaceuticals, Inc.Phase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Hereditary Angioedema - Type 2 cohort.

Asset / SponsorPhaseRating
Deucrictibant
Pharvaris Netherlands B.V.
Phase 3BBB

Same molecule, other indications

Adx-324 is also rated in:

HAEDormant
BB
Indicative ·
66 / 100
View asset →
hereditary angioedemaDormant
BB
Indicative ·
64 / 100
View asset →
hereditary angioedema type 1Dormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →